Benjamin Hibbert1, Bradley Hayley1, Robert S Beanlands1, Michel Le May1, Richard Davies1, Derek So1, Jean-François Marquis1, Marino Labinaz1, Michael Froeschl1, Edward R O'Brien1, Ian G Burwash1, George A Wells1, Ali Pourdjabbar1, Trevor Simard1, Harold Atkins1, Christopher Glover2. 1. Division of Cardiology (Hibbert, Hayley, Beanlands, Le May, Davies, So, Marquis, Labinaz, Froeschl, O'Brien, Burwash, Wells, Pourdjabbar, Simard, Glover), Department of Medicine, University of Ottawa Heart Institute, Ottawa, Ont.; Libin Cardiovascular Institute (O'Brien), Calgary, Alta.; Division of Hematology (Atkins), Department of Medicine, The Ottawa Hospital and University of Ottawa, Ottawa, Ont. 2. Division of Cardiology (Hibbert, Hayley, Beanlands, Le May, Davies, So, Marquis, Labinaz, Froeschl, O'Brien, Burwash, Wells, Pourdjabbar, Simard, Glover), Department of Medicine, University of Ottawa Heart Institute, Ottawa, Ont.; Libin Cardiovascular Institute (O'Brien), Calgary, Alta.; Division of Hematology (Atkins), Department of Medicine, The Ottawa Hospital and University of Ottawa, Ottawa, Ont. cglover@ottawaheart.ca.
Abstract
BACKGROUND: Small studies have yielded divergent results for administration of granulocyte colony-stimulating factor (G-CSF) after acute myocardial infarction. Adequately powered studies involving patients with at least moderate left ventricular dysfunction are lacking. METHODS:Patients with left ventricular ejection fraction less than 45% after anterior-wall myocardial infarction were treated with G-CSF (10 μg/kg daily for 4 days) or placebo. After initial randomization of 86 patients, 41 in the placebo group and 39 in the G-CSF group completed 6-month follow-up and underwent measurement of left ventricular ejection fraction by radionuclide angiography. RESULTS: Baseline and 6-week mean ejection fraction was similar for the G-CSF and placebo groups: 34.8% (95% confidence interval [CI] 32.6%-37.0%) v. 36.4% (95% CI 33.5%-39.2%) at baseline and 39.8% (95% CI 36.2%-43.4%) v. 43.1% (95% CI 39.2%-47.0%) at 6 weeks. However, G-CSF therapy was associated with a lower ejection fraction at 6 months relative to placebo (40.8% [95% CI 37.4%-44.2%] v. 46.0% [95% CI 42.7%-44.3%]). Both groups had improved left ventricular function, but change in left ventricular ejection fraction was lower in patients treated with G-CSF than in those who received placebo (5.7 [95% CI 3.4-8.1] percentage points v. 9.2 [95% CI 6.3-12.1] percentage points). One or more of a composite of several major adverse cardiac events occurred in 8 patients (19%) within each group, with similar rates of target-vessel revascularization. INTERPRETATION: In patients with moderate left ventricular dysfunction following anterior-wall infarction, G-CSF therapy was associated with a lower 6-month left ventricular ejection fraction but no increased risk of major adverse cardiac events. Future studies of G-CSF in patients with left ventricular dysfunction should be monitored closely for safety. TRIAL REGISTRATION: ClinicalTrials.gov, no. NCT00394498.
RCT Entities:
BACKGROUND: Small studies have yielded divergent results for administration of granulocyte colony-stimulating factor (G-CSF) after acute myocardial infarction. Adequately powered studies involving patients with at least moderate left ventricular dysfunction are lacking. METHODS:Patients with left ventricular ejection fraction less than 45% after anterior-wall myocardial infarction were treated with G-CSF (10 μg/kg daily for 4 days) or placebo. After initial randomization of 86 patients, 41 in the placebo group and 39 in the G-CSF group completed 6-month follow-up and underwent measurement of left ventricular ejection fraction by radionuclide angiography. RESULTS: Baseline and 6-week mean ejection fraction was similar for the G-CSF and placebo groups: 34.8% (95% confidence interval [CI] 32.6%-37.0%) v. 36.4% (95% CI 33.5%-39.2%) at baseline and 39.8% (95% CI 36.2%-43.4%) v. 43.1% (95% CI 39.2%-47.0%) at 6 weeks. However, G-CSF therapy was associated with a lower ejection fraction at 6 months relative to placebo (40.8% [95% CI 37.4%-44.2%] v. 46.0% [95% CI 42.7%-44.3%]). Both groups had improved left ventricular function, but change in left ventricular ejection fraction was lower in patients treated with G-CSF than in those who received placebo (5.7 [95% CI 3.4-8.1] percentage points v. 9.2 [95% CI 6.3-12.1] percentage points). One or more of a composite of several major adverse cardiac events occurred in 8 patients (19%) within each group, with similar rates of target-vessel revascularization. INTERPRETATION: In patients with moderate left ventricular dysfunction following anterior-wall infarction, G-CSF therapy was associated with a lower 6-month left ventricular ejection fraction but no increased risk of major adverse cardiac events. Future studies of G-CSF in patients with left ventricular dysfunction should be monitored closely for safety. TRIAL REGISTRATION: ClinicalTrials.gov, no. NCT00394498.
Authors: G G L Biondi-Zoccai; A Abate; R Bussani; D Camilot; F D Giorgio; M-P D Marino; F Silvestri; F Baldi; L M Biasucci; A Baldi Journal: Heart Date: 2005-01 Impact factor: 5.994
Authors: Michel R Le May; Richard F Davies; Richard Dionne; Justin Maloney; John Trickett; Derek So; Andrew Ha; Heather Sherrard; Chris Glover; Jean-François Marquis; Edward R O'Brien; Ian G Stiell; Pierre Poirier; Marino Labinaz Journal: Am J Cardiol Date: 2006-09-28 Impact factor: 2.778
Authors: Birgit Assmus; Jörg Honold; Volker Schächinger; Martina B Britten; Ulrich Fischer-Rasokat; Ralf Lehmann; Claudius Teupe; Katrin Pistorius; Hans Martin; Nasreddin D Abolmaali; Torsten Tonn; Stefanie Dimmeler; Andreas M Zeiher Journal: N Engl J Med Date: 2006-09-21 Impact factor: 91.245
Authors: Nirat Beohar; James D Flaherty; Charles J Davidson; Mladen Vidovich; Seema Singhal; Jonathan A Rapp; Ata Erdogan; Daniel C Lee; Chidambaram Rammohan; Adam Brodsky; Edwin Wu; Karen Pieper; Renu Virmani; Robert O Bonow; Jayesh Mehta Journal: Catheter Cardiovasc Interv Date: 2007-02-01 Impact factor: 2.692
Authors: Jonathan M Hill; Mushabbar A Syed; Andrew E Arai; Tiffany M Powell; Jonathan D Paul; Gloria Zalos; Elizabeth J Read; Hanh M Khuu; Susan F Leitman; McDonald Horne; Gyorgy Csako; Cynthia E Dunbar; Myron A Waclawiw; Richard O Cannon Journal: J Am Coll Cardiol Date: 2005-11-01 Impact factor: 24.094
Authors: Volker Schächinger; Sandra Erbs; Albrecht Elsässer; Werner Haberbosch; Rainer Hambrecht; Hans Hölschermann; Jiangtao Yu; Roberto Corti; Detlef G Mathey; Christian W Hamm; Tim Süselbeck; Birgit Assmus; Torsten Tonn; Stefanie Dimmeler; Andreas M Zeiher Journal: N Engl J Med Date: 2006-09-21 Impact factor: 91.245
Authors: Stephen G Ellis; Marc S Penn; Brian Bolwell; Mario Garcia; Matthews Chacko; Thomas Wang; Kelly J Brezina; Gerry McConnell; Eric J Topol Journal: Am Heart J Date: 2006-12 Impact factor: 4.749
Authors: Francisco Fernández-Avilés; Ricardo Sanz-Ruiz; Andreu M Climent; Lina Badimon; Roberto Bolli; Dominique Charron; Valentin Fuster; Stefan Janssens; Jens Kastrup; Hyo-Soo Kim; Thomas F Lüscher; John F Martin; Philippe Menasché; Robert D Simari; Gregg W Stone; Andre Terzic; James T Willerson; Joseph C Wu Journal: Eur Heart J Date: 2017-09-01 Impact factor: 29.983
Authors: Stephanie Wallner; Sebastian Peters; Claudia Pitzer; Herbert Resch; Ulrich Bogdahn; Armin Schneider Journal: Front Cell Dev Biol Date: 2015-08-07